JP7659553B2 - アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト - Google Patents

アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト Download PDF

Info

Publication number
JP7659553B2
JP7659553B2 JP2022525958A JP2022525958A JP7659553B2 JP 7659553 B2 JP7659553 B2 JP 7659553B2 JP 2022525958 A JP2022525958 A JP 2022525958A JP 2022525958 A JP2022525958 A JP 2022525958A JP 7659553 B2 JP7659553 B2 JP 7659553B2
Authority
JP
Japan
Prior art keywords
compound
cancer
equiv
mmol
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513655A (ja
JP2023513655A5 (enExample
Inventor
コスフォード，ニコラス，デイビッド，ピーター
ハイマン，ドミニク
テリーテ，ピーター
クマール チャンダー，スミト
パシュ，ラーズ
バタ，ニコル
Original Assignee
サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート filed Critical サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート
Publication of JP2023513655A publication Critical patent/JP2023513655A/ja
Publication of JP2023513655A5 publication Critical patent/JP2023513655A5/ja
Priority to JP2025054317A priority Critical patent/JP2025118594A/ja
Application granted granted Critical
Publication of JP7659553B2 publication Critical patent/JP7659553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2022525958A 2019-11-08 2020-11-06 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト Active JP7659553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025054317A JP2025118594A (ja) 2019-11-08 2025-03-27 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933190P 2019-11-08 2019-11-08
US62/933,190 2019-11-08
PCT/US2020/059552 WO2021092500A1 (en) 2019-11-08 2020-11-06 Inhibitor of apoptosis (iap) protein antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025054317A Division JP2025118594A (ja) 2019-11-08 2025-03-27 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Publications (3)

Publication Number Publication Date
JP2023513655A JP2023513655A (ja) 2023-04-03
JP2023513655A5 JP2023513655A5 (enExample) 2023-10-18
JP7659553B2 true JP7659553B2 (ja) 2025-04-09

Family

ID=75849612

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525958A Active JP7659553B2 (ja) 2019-11-08 2020-11-06 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト
JP2025054317A Pending JP2025118594A (ja) 2019-11-08 2025-03-27 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025054317A Pending JP2025118594A (ja) 2019-11-08 2025-03-27 アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Country Status (6)

Country Link
US (1) US12678509B2 (enExample)
EP (1) EP4058454A4 (enExample)
JP (2) JP7659553B2 (enExample)
AU (1) AU2020380818B2 (enExample)
CA (1) CA3160666A1 (enExample)
WO (1) WO2021092500A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025118594A (ja) * 2019-11-08 2025-08-13 サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113613724B (zh) * 2018-11-30 2024-11-08 葛兰素史克知识产权开发有限公司 可用于hiv疗法的化合物
EP4143198A4 (en) * 2020-04-30 2024-05-01 Sanford Burnham Prebys Medical Discovery Institute INHIBITOR OF APOPTOSIS PROTEIN ANTAGONISTS (API)
CN117304253A (zh) * 2022-06-22 2023-12-29 中国药科大学 一种二氮杂双环拟肽衍生物的制备方法及应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536204A (ja) 2006-05-05 2009-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
JP2012529482A (ja) 2009-06-12 2012-11-22 アストラゼネカ アクチボラグ ２，３−ジヒドロ−１ｈ−インデン化合物および癌を治療するためのその使用
JP2013509429A (ja) 2009-10-28 2013-03-14 ジョイアント ファーマスーティカルズ、インク． 二量体Ｓｍａｃ模倣薬
JP2016501223A (ja) 2012-11-30 2016-01-18 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
JP2017522273A (ja) 2014-06-04 2017-08-10 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
JP2022509869A (ja) 2018-11-30 2022-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｈｉｖ療法に有用な化合物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5455242A (en) 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
PT669936E (pt) 1992-10-30 2001-04-30 Merrell Pharma Inc Derivados de lactama biciclica de mercaptoacetilamida uteis como inibidores de encefalinase e de ace
US5508272A (en) 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
FR2803594B1 (fr) 2000-01-11 2002-07-19 Centre Nat Rech Scient Oligomeres de mimes contraints non peptidiques de dipeptides ou de tripeptides, et leurs utilisations
WO2004007529A2 (en) 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
BRPI0506883A (pt) 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
US7345081B2 (en) 2004-03-23 2008-03-18 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
PL2253614T3 (pl) 2004-04-07 2013-03-29 Novartis Ag Inhibitory IAP
KR100926203B1 (ko) 2004-07-02 2009-11-09 제넨테크, 인크. Ｉａｐ의 억제제
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
BRPI0513310A (pt) 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
JP5230865B2 (ja) 2004-07-15 2013-07-10 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ結合性化合物
MX2007007195A (es) 2004-12-20 2007-10-08 Genentech Inc Inhibidores de pirrolidina de iap.
EA012810B1 (ru) 2005-02-25 2009-12-30 Тетралоджик Фармасеутикалс Димерные ингибиторы ингибиторов белков апоптоза (iap)
AU2006255084A1 (en) 2005-06-08 2006-12-14 Novartis Ag Organic compounds
WO2007041775A1 (en) 2005-10-10 2007-04-19 The University Of Queensland Cysteine protease inhibitors incorporating azide groups
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007107008A1 (en) 2006-03-22 2007-09-27 Innodia Inc. Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
CA2670726A1 (en) 2006-12-07 2008-06-19 Novartis Ag 6-oxo-1, 6-dihydropyrimidin-2-yls in the treatment of proliferative diseases
US20090010941A1 (en) 2007-04-09 2009-01-08 University Of Massachusetts Methods for treating HIV
CA2684169C (en) 2007-04-12 2012-06-19 Joyant Pharmaceuticals, Inc. Smac mimetic dimers and trimers useful as anti-cancer agents
WO2008128171A2 (en) 2007-04-13 2008-10-23 The Regents Of The University Of Michigan Diazo bicyclic smac mimetics and the uses thereof
NZ598890A (en) 2007-04-30 2013-10-25 Genentech Inc Inhibitors of iap
CA2591126A1 (en) 2007-06-08 2008-12-08 Kanata Chemical Technologies Inc. Process for the preparation of aminiphosphine ligands and their use in metal catalysts
EP2058312A1 (en) 2007-11-09 2009-05-13 Universita' degli Studi di Milano SMAC mimetic compounds as apoptosis inducers
US8445473B2 (en) 2008-04-11 2013-05-21 The Regents Of The University Of Michigan Heteroaryl-substituted bicyclic Smac mimetics and the uses thereof
CN102159557A (zh) 2008-09-22 2011-08-17 弗·哈夫曼-拉罗切有限公司 哌嗪d3和5-ht2a受体调节剂
US8642544B2 (en) 2009-04-01 2014-02-04 Amylin Pharmaceuticals, Llc N-terminus conformationally constrained GLP-1 receptor agonist compounds
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
WO2011082285A1 (en) 2009-12-30 2011-07-07 Avila Therapeutics, Inc. Ligand-directed covalent modification of protein
EP3351249A1 (en) 2010-01-27 2018-07-25 VIIV Healthcare Company Antiviral therapy
US9346852B2 (en) 2011-03-14 2016-05-24 Bristol-Myers Scuibb Company Substituted adipic acid amides and uses thereof
US20150174235A1 (en) 2012-06-06 2015-06-25 Bionor Immuno As Vaccine
AU2013306087B2 (en) * 2012-08-23 2017-08-10 The Regents Of The University Of Michigan Bivalent inhibitors of IAP proteins and therapeutic methods using the same
RU2018132559A (ru) * 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
US10870663B2 (en) * 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
US12678509B2 (en) * 2019-11-08 2026-07-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists
EP4143198A4 (en) 2020-04-30 2024-05-01 Sanford Burnham Prebys Medical Discovery Institute INHIBITOR OF APOPTOSIS PROTEIN ANTAGONISTS (API)
US20250129099A1 (en) 2021-11-04 2025-04-24 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009536204A (ja) 2006-05-05 2009-10-08 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 二価ｓｍａｃ模倣物およびその使用
JP2012529482A (ja) 2009-06-12 2012-11-22 アストラゼネカ アクチボラグ ２，３−ジヒドロ−１ｈ−インデン化合物および癌を治療するためのその使用
JP2013509429A (ja) 2009-10-28 2013-03-14 ジョイアント ファーマスーティカルズ、インク． 二量体Ｓｍａｃ模倣薬
JP2016501223A (ja) 2012-11-30 2016-01-18 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
JP2017522273A (ja) 2014-06-04 2017-08-10 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
JP2022509869A (ja) 2018-11-30 2022-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド Ｈｉｖ療法に有用な化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Haiying Sun, Liu Liu, Jianfeng Lu, Longchuan Bai, Xiaoqin Li, Zaneta Nikolovska-Coleska, Donna McEachern, Chao-Yie Yang, Su Qiu, Han Yi, Duxin Sun and Shaomeng Wang，Potent Bivalent Smac Mimetics: Effect of the Linker on Binding to Inhibitor of Apoptosis Proteins (IAPs) and Anticancer Activity，Journal of Medicinal Chemistry，米国，American Chemical Society，2011年04月04日，54(9)，3306-3318
Jianfeng Lu, Longchuan Bai, Haiying Sun, Zaneta Nikolovska-Coleska, Donna McEachern, Su Qiu, Rebecca S. Miller, Han Yi, Sanjeev Shangary, Yi Sun, Jennifer L. Meagher, Jeanne A. Stuckey, and Shaomeng Wang，SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP，Cancer Research，米国，American Association for Cancer Research，2008年11月15日，68(22)，9384-9393
MITCHELL VAMOS; ET AL，EXPEDIENT SYNTHESIS OF HIGHLY POTENT ANTAGONISTS OF INHIBITOR OF APOPTOSIS PROTEINS (IAPS) WITH UNIQ，ACS CHEMICAL BIOLOGY，2013年04月19日，VOL:8, NR:4，PAGE(S):725-732，https://doi.org/10.1021/cb3005512

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025118594A (ja) * 2019-11-08 2025-08-13 サンフォード バーンハム プレビス メディカル ディスカバリー インスティテュート アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト

Also Published As

Publication number Publication date
WO2021092500A1 (en) 2021-05-14
US20230115837A1 (en) 2023-04-13
AU2020380818A1 (en) 2022-06-02
JP2023513655A (ja) 2023-04-03
AU2020380818B2 (en) 2026-05-21
US12678509B2 (en) 2026-07-14
JP2025118594A (ja) 2025-08-13
EP4058454A1 (en) 2022-09-21
EP4058454A4 (en) 2023-12-13
CA3160666A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
US11912786B2 (en) Inhibitor of apoptosis protein (IAP) antagonists
WO2020123675A1 (en) Compositions and methods for the treatment of cancer
AU2020380818B2 (en) Inhibitor of apoptosis (IAP) protein antagonists
US9932329B2 (en) Benzimidazole derivatives as RLK and ITK inhibitors
US20240132493A1 (en) Imidazopyridine derivatives as sting agonists
US12325691B2 (en) Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain
AU2021265826B2 (en) Inhibitor of apoptosis (IAP) protein antagonists
JP2025118609A (ja) Ｎｕｒｒ１受容体調節因子
WO2023081290A1 (en) Inhibitor of apoptosis (iap) protein antagonists
WO2020028525A1 (en) Sumo inhibitor compounds and uses thereof
WO2025240412A1 (en) Methods for the treatment of cancer
WO2025240416A1 (en) Compositions and methods for the treatment of cancer
CN116848100A (zh) Notch抑制剂及其用途

Legal Events

Date Code Title Description
RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231006

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250303

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250328

R150 Certificate of patent or registration of utility model

Ref document number: 7659553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150